Skip to main content

Evidence boundary

Approval is not adoption

NEUVIOR distinguishes verified fact, development status, operating doctrine and future intent so that public communications do not outrun the evidence available.

View the public evidenceAsk an evidence question
Evidence | Exact source, date, scope and statusFunding | Selection for defined project workUnknown | Preserved rather than upgraded

Claim classes

Every statement should declare what kind of truth it represents.

The same page may contain current fact, current status, operating doctrine and future intent. Labels prevent those categories from collapsing into one promotional story.

01

Current fact

Supported by an identified source with relevant scope and date.

02

Current status

A time bound description of development, evaluation or assurance.

03

Operating doctrine

A rule that governs design or conduct but is not proof of implementation.

04

Future intent

A strategic direction that remains subject to evidence and decision gates.

Public funding

Selection for project work is meaningful, but limited evidence.

Innovation funding evidences selection for defined project work. It does not prove deployment, clinical value, commercial demand, adoption or institutional endorsement.

A completed feasibility project should remain in the historical record unless new evidence supports an active commercial status.

Read the project support recordInvestor overview
01

Project selected

A funder supported work within a defined scope and period.

Supported
02

Product deployed

Requires separate evidence of a real environment, adopter and release.

Not implied
03

Outcome realised

Requires independent evidence connecting activity to the claimed result.

Not implied

Publication gate

Remove, narrow or hold what the source cannot support.

A claim should survive exact source review, not merely sound plausible. Unknown remains unknown until a relevant record changes that status.

Human decision requiredProceed only inside an evidenced and governed scope.
01

Exact support

Publish with source, date, scope, status and material limitation.

Continue
02

Partial support

Narrow the wording to the portion the evidence can carry.

Narrow
03

Conflict or absence

Remove or hold the statement until the record is reconciled.

No go

Classified public record

Open the classified public record

ANALYSIS + EVIDENCE BOUNDARY

Read the argument. Verify the product separately.

Published analysis can explain why governance matters. It cannot evidence security, clinical authority, certification, product readiness or local approval. Use the dated NEUVIOR records for that.

  1. AI Ethics Now / University of Warwick IATLPodcast appearance

    AI and Accountability: When Does a Suggestion Become a Decision?

    Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.

    Hear where an AI suggestion becomes a decision
  2. TechRadar ProContributed opinion

    Five questions to test whether an AI stack is truly under your control

    In TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.

    Test provenance, control and safe exit
  3. NEUVIOR InsightsNEUVIOR analysis

    From pilot theatre to financial grip: how NHS CFOs should evaluate AI in medicines optimisation

    NHS finance leaders do not need another AI pitch. They need a disciplined way to decide whether a technology can release value within the financial rules they are already being held to.

    See how a finance leader should test an AI claim
Read the governance arguments

NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.

Make the next step useful

Bring the problem that needs a clearer decision.

Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.

View the public evidenceSpeak with NEUVIOR

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01What is NEUVIOR?

NEUVIOR is a pharmaceutical company registered in Scotland. It is building capabilities across medicines intelligence, governed technology and longer term development. PHARMORIS is its immediate product priority.

02What does NEUVIOR build today?

NEUVIOR is developing PHARMORIS, a human-governed medicines operations system in controlled, non-production development. It is intended to connect evidence, decisions, accountable work and value review. No independent TRL, deployment, customer adoption or clinical validation is claimed.

03What is PHARMORIS by NEUVIOR?

PHARMORIS is a configurable medicines operations system under controlled development. It is designed to help authorised teams progress medicine opportunities from evidence linked to its source, through an owned ActionCase, a human decision, delivery and review.

04Who founded NEUVIOR?

Varun Sharma is the Founder, CEO and CTO of NEUVIOR and leads the company and PHARMORIS product architecture.

05Where does NEUVIOR have a presence?

NEUVIOR works across Glasgow, London and Mumbai. Glasgow is the company origin and registered Scottish base. London supports commercial activity led by the founder. Mumbai supports market engagement in India and relationships across the pharmaceutical sector. These are different forms of presence. They do not imply three registered offices or regulated facilities.